Next-Generation DNA NanoVectors – An Alternative Vector Platform for the Safe, Rapid, and Persistent Manufacture of Recombinant T cells for Autologous T Cell Immunotherapy
Time: 11:30 am
day: Day 1 – Track B – Morning
Details:
- A novel non-integrating minimally sized DNA vector platform named nS/MARt was used to efficiently engineer human T lymphocytes
- When nS/MARt technology was combined with GMPcompliant MaxCyte Flow Electroporation®, the production of clinical scale recombinant CAR T cells with enhanced antitumor activity was achieved in only five days
- The key advantages of the nS/MARt vector platform include simplified vector engineering, low immunogenicity, and low production costs enabling rapid manufacture of safe and effective CAR T cell therapies for thousands of patients
